Literature DB >> 790287

The paradoxical effect of adrenergic and methylxanthine drugs in cystic fibrosis.

G G Shapiro, J Bamman, P Kanarek, C W Bierman.   

Abstract

This study examined the effect of aerosolized isoproterenol and oral theophylline on pulmonary function in cystic fibrosis (CF) to determine how often these drugs are beneficial and whether there is a correlation between response to isoproterenol and response to oral theophylline. After obtaining baseline pulmonary function tests before and after isoproterenol aerosol, 12 patients with CF were put on a double-blind trial of high-dosage theophylline (10 mg/kg three times per day) or placebo for four weeks and were then switched to the alternate regimen for the next four weeks. Patients had weekly evaluations of pulmonary function and plasma theophylline determinations. Gastrointestinal side effects were common with theophylline. The responses to aerosolized bronchodilators were inconsistent from week to week. After aerosolized bronchodilator, five of 12 patients had an average increase of 10% or more in FEF45%-55% and FEF70%-80%. While taking oral theophylline, five patients had a 10% or more decrease in FEF 45%-55% and six patients had a decrease in FEF70%-80%. We conclude that there was no concordance between response to isoproterenol and theophylline, and that adrenergic and methylxanthine drugs must be used with caution in patients with CF.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 790287

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

Review 1.  Airway reactivity in cystic fibrosis.

Authors:  R S Tepper; H Eigen
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.

Authors:  S P Conway; A Watson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 3.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 4.  Exercise response and rehabilitation in cystic fibrosis.

Authors:  G J Canny; H Levison
Journal:  Sports Med       Date:  1987 Mar-Apr       Impact factor: 11.136

Review 5.  What is asthma?

Authors:  S Godfrey
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

6.  Bioavailability and pharmacokinetics of theophylline following plain uncoated and sustained-release dosage forms in relation to smoking habit. II. Multiple dose study.

Authors:  T Ishizaki; Y Horai; T Sasaki; K Chiba; A Ohnishi; T Suganuma; G Tsujimoto; H Echizen; T Okaniwa
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Airways reactivity in patients with CF.

Authors:  Miles Weinberger
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  The adrenergic system in lymphocytes from children with cystic fibrosis.

Authors:  A Schuster; A Elsen; M Griese; G Kusenbach; D Reinhardt
Journal:  Klin Wochenschr       Date:  1989-08-17

9.  Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

Authors:  R Demnati; M C Michoud; A Jeanneret-Grosjean; H Ong; P Du Souich
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 10.  Therapeutic monitoring of theophylline. Rationale and current status.

Authors:  C W Bierman; P V Williams
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.